These conversions matter when you and your clinician agree on a weekly target and whether you’ll inject IM (into muscle) or SC (into the fat just beneath the skin). In practice, a common testosterone cypionate dosage window for TRT is roughly 75–150 mg per week (often split into two shots); the exact number is individualized. Drug references explicitly note that dosing should be individualized to response and adverse effects, not set-and-forget (see the Drugs.com dosage monograph). Monitoring typically includes periodic testosterone levels plus safety checks such as hematocrit, PSA (for men), blood pressure, and lipids to ensure therapy stays effective and safe. The idea isn’t to raise the total—just to distribute it for smoother physiology. Dosing should follow local product information and the same monitoring principles used for all injectables (see Drugs.com for labeled dosing references and the Endocrine Society guideline for monitoring). You may see the phrase "sustanon 250 dosage 1ml per week" online; treat it as a discussion point, not a universal standard. Brand availability, precautions, and injection logistics are outlined on Mayo Clinic’s route-specific page and in the Endocrine Society guideline. Long-acting testosterone undecanoate (e.g., Aveed® in the U.S.) is typically administered in clinic because of rare but serious oil-embolism reactions. Label presentations and administration details for injectable formulations are summarized on Mayo Clinic’s drug page and in the Drugs.com monograph. For others, particularly those more sensitive to hormone fluctuations, twice-weekly or daily dosing may be worth the added effort. If you already feel great and have no side effects on a weekly schedule, switching to more frequent dosing is not going to increase effects, it will blunt/smooth effects. For most men, though, the benefits of twice-weekly injections are more about comfort and stability than rather than greater effect. For the majority of men, once-weekly injections deliver the best balance of effectiveness, convenience, and adherence. Each testosterone injection raises your blood levels and then gradually drifts down as the hormone is metabolized. A weekly plan around 100 mg (cypionate/enanthate) can produce mid-range levels in certain patients, especially when injections are split to minimize peaks and troughs. While weekly dosing is not mandatory for every patient, the evidence points to improved hormone stability and symptom control when injections are spaced closer together. A side effects comparison reveals that daily injections tend to produce more stable serum testosterone levels, potentially reducing peak-related adverse effects such as mood swings and erythrocytosis. Maintaining stable serum testosterone levels is crucial for optimizing the efficacy and safety of bi-weekly testosterone injection protocols. The bi-weekly testosterone injection protocol typically involves administering higher doses at 14-day intervals to maintain therapeutic hormone levels. Weekly injections balance hormone stability with convenience, while bi-weekly dosing produces larger hormonal fluctuations, potentially increasing side effects like fluid retention and gynecomastia. A safe testosterone dosage is the lowest amount that controls symptoms while keeping safety labs within accepted limits. The ISSWSH 2021 guideline likewise recommends transdermal options (e.g., gels/creams titrated down from male products) with careful monitoring of testosterone, SHBG, and clinical response (ISSWSH Clinical Practice Guideline, 2021). For cisgender women, systemic testosterone is occasionally used for distressing low sexual desire after other causes are addressed—specifically, hypoactive sexual desire disorder (HSDD). Most start conservatively, reassess at 3–6 months, and adjust by small increments (e.g., 10–20 mg/week) while watching hematocrit, PSA, blood pressure, and lipids. Splitting the total tends to reduce peaks and troughs and may improve how you feel between shots. This prevents accidental over- or under-dosing and keeps labs interpretable. Decisions at this level should be made with a clinician who is monitoring labs at appropriate intervals (see cautions across the AUA guideline and dosing context in the Drugs.com monograph). One hundred and ninety-two male participants received either a single dose of testosterone (150 mg) or a placebo and performed a prosocial and self-benefitting reinforcement learning task. Conversely, less frequent injections can cause peaks and troughs in hormone levels, potentially exacerbating mood instability. More frequent administration, such as daily injections, tends to maintain steadier testosterone plasma concentrations, reducing fluctuations that may precipitate mood swings and energy variability. Thus, the choice of injection interval involves balancing hormone stability against patient preference and injection tolerability to optimize TRT outcomes. Weekly or bi-weekly schedules, while offering improved injection comfort, often exhibit greater hormonal variability that requires careful dose titration to mitigate symptomatic oscillations. Daily injections tend to produce minimal hormone fluctuations, maintaining near steady-state testosterone concentrations that optimize receptor engagement and symptom control. Injection consistency is vital to minimize peaks and troughs in testosterone concentrations, thereby stabilizing hormone levels within the therapeutic range. Each block started with a new pair of symbols and consisted of 16 trials/choices. This way participants learned which symbol to choose to maximize the rewards in the long run. In addition, when participants were observed, a red frame was shown on their computer’s screen and the displays of the participants’ computers were transmitted onto the observers‘ laptop screens. The observers were seated at a desk with a laptop and had an equal view of all the participants. In the observed condition, two female observers, introduced as NGO association representatives entered the room and watched participants perform the task. In the private condition, participants were informed that their performance is completely anonymous and no one (including the experimenter) would know how much money they would earn for themselves and the charitable organization. After data collection was complete, saliva samples were analyzed by liquid chromatography-tandem mass spectrometry.